Shareholder Vote

Common Shares, Without Par Value   ABT       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549       FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   April 25, 2025 Date of Report (Date of earliest event reported)     ABBOTT LABORATORIES (Exact name of registrant as specified in charter)       Illinois   1-2189   36-0698440 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)       100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 224 ) 667-6100   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities Registered Pursuant to Section 12(b) of the Act:   Title of Each Class Trading Symbol(s) Name of Each Exchange  on Which Registered Common Shares, Without Par Value ABT New York Stock Exchange Chicago Stock Exchange, Inc.   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨             Item 5.07 — Submission of Matters to a Vote of Security Holders.   Abbott held its Annual Meeting of Shareholders on April 25, 2025. The following is a summary of the matters voted on at that meeting.   (1) The shareholders elected Abbott’s entire Board of Directors. The persons elected to Abbott’s Board of Directors and the number of shares cast for, the number against, the number abstaining, and the number of broker non-votes, with respect to each of these persons, were as follows:   Name   Votes For     Votes Against     Abstain     Broker Non-Votes   Robert J. Alpern, M.D.     1,327,438,854       33,059,124       1,692,999       172,532,563   Claire Babineaux-Fontenot     1,353,692,234       6,825,428       1,673,315       172,532,563   Sally E. Blount, Ph.D.     1,336,357,728       23,419,311       2,413,938       172,532,563   Robert B. Ford     1,264,478,626       91,618,170       6,094,181       172,532,563   Paola Gonzalez     1,354,420,876       5,453,437       2,316,664       172,532,563   Michelle A. Kumbier     1,351,012,042       9,433,083       1,745,852       172,532,563   Darren W. McDew     1,350,972,305       8,767,072       2,451,601       172,532,563   Nancy McKinstry     1,116,607,201       243,925,809       1,657,967       172,532,563   Michael G. O’Grady     1,333,186,431       27,251,169       1,753,377       172,532,563   Michael F. Roman     1,344,216,165       16,199,533       1,775,279       172,532,563   Daniel J. Starks     1,305,438,905       55,076,532       1,675,540       172,532,563   John G. Stratton     1,187,966,267       172,531,567       1,693,143       172,532,563     (2) The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors. The number of shares cast in favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes were as follows:   For     Against     Abstain     Broker Non-Votes     1,495,642,212       36,586,494       2,494,834       0     (3) The shareholders approved the compensation of Abbott’s named executive officers listed in the proxy statement for the Annual Meeting, with 89.90 percent of the votes cast voting “For” the proposal. The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows:   For     Against     Abstain     Broker Non-Votes     1,224,503,868       130,699,445       6,987,664       172,532,563           SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     ABBOTT LABORATORIES       Date: April 28, 2025 By: /s/ PHILIP P. BOUDREAU     Philip P. Boudreau     Executive Vice President, Finance     and Chief Financial Officer